The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients

C. Rajda, K. Bencsik, J. Füvesi, E. Seres, L. Vécsei, Jonas Bergquist

Research output: Article

18 Citations (Scopus)

Abstract

The mutual involvement of dopamine and its metabolites in the nervous and immune systems has the potential to provide information on the interaction of these two systems. During a 24-hour period, we used capillary electrophoresis with electrochemical detection to repeatedly measure the intracellular catecholamine concentrations in the peripheral blood lymphocytes of relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon (IFN)-beta-1b (n = 13), and those of IFN-naïve RRMS patients receiving their first IFN-beta-1a injection (n = 19) during this study, and compared them with the levels in healthy controls (n = 12). At baseline, the norepinephrine level was significantly decreased (P = 0.003) in the long-term IFN MS patients compared with the controls. The Time × Group interactions for dopamine (P = 0.5854) and norepinephrine (P = 0.6192) were not significant. The group effects for the individual drugs were P = 0.3529 and 0.1282, respectively. The lower norepinephrine level at baseline in the long-term IFN MS group suggests an immunologically stable phase, in line with our previous findings. This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Further studies are necessary to elucidate the immune reactions affected by the catecholamines in MS and to evaluate the roles of these potential immunotransmitters.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalMultiple Sclerosis
Volume12
Issue number3
DOIs
Publication statusPublished - jún. 2006

Fingerprint

Interferon-beta
Multiple Sclerosis
Norepinephrine
Lymphocytes
Interferons
Catecholamines
Relapsing-Remitting Multiple Sclerosis
Dopamine
Capillary Electrophoresis
Nervous System
Immune System
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. / Rajda, C.; Bencsik, K.; Füvesi, J.; Seres, E.; Vécsei, L.; Bergquist, Jonas.

In: Multiple Sclerosis, Vol. 12, No. 3, 06.2006, p. 265-270.

Research output: Article

@article{0c7f48ad5a8f434e89b6272edbef5e64,
title = "The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients",
abstract = "The mutual involvement of dopamine and its metabolites in the nervous and immune systems has the potential to provide information on the interaction of these two systems. During a 24-hour period, we used capillary electrophoresis with electrochemical detection to repeatedly measure the intracellular catecholamine concentrations in the peripheral blood lymphocytes of relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon (IFN)-beta-1b (n = 13), and those of IFN-na{\"i}ve RRMS patients receiving their first IFN-beta-1a injection (n = 19) during this study, and compared them with the levels in healthy controls (n = 12). At baseline, the norepinephrine level was significantly decreased (P = 0.003) in the long-term IFN MS patients compared with the controls. The Time × Group interactions for dopamine (P = 0.5854) and norepinephrine (P = 0.6192) were not significant. The group effects for the individual drugs were P = 0.3529 and 0.1282, respectively. The lower norepinephrine level at baseline in the long-term IFN MS group suggests an immunologically stable phase, in line with our previous findings. This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Further studies are necessary to elucidate the immune reactions affected by the catecholamines in MS and to evaluate the roles of these potential immunotransmitters.",
keywords = "Capillary electrophoresis, Catecholamine, Dopamine, Human peripheral blood lymphocyte, Interferon-beta, Multiple sclerosis, Norepinephrine, Relapsing-remitting",
author = "C. Rajda and K. Bencsik and J. F{\"u}vesi and E. Seres and L. V{\'e}csei and Jonas Bergquist",
year = "2006",
month = "6",
doi = "10.1191/135248506ms1269oa",
language = "English",
volume = "12",
pages = "265--270",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients

AU - Rajda, C.

AU - Bencsik, K.

AU - Füvesi, J.

AU - Seres, E.

AU - Vécsei, L.

AU - Bergquist, Jonas

PY - 2006/6

Y1 - 2006/6

N2 - The mutual involvement of dopamine and its metabolites in the nervous and immune systems has the potential to provide information on the interaction of these two systems. During a 24-hour period, we used capillary electrophoresis with electrochemical detection to repeatedly measure the intracellular catecholamine concentrations in the peripheral blood lymphocytes of relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon (IFN)-beta-1b (n = 13), and those of IFN-naïve RRMS patients receiving their first IFN-beta-1a injection (n = 19) during this study, and compared them with the levels in healthy controls (n = 12). At baseline, the norepinephrine level was significantly decreased (P = 0.003) in the long-term IFN MS patients compared with the controls. The Time × Group interactions for dopamine (P = 0.5854) and norepinephrine (P = 0.6192) were not significant. The group effects for the individual drugs were P = 0.3529 and 0.1282, respectively. The lower norepinephrine level at baseline in the long-term IFN MS group suggests an immunologically stable phase, in line with our previous findings. This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Further studies are necessary to elucidate the immune reactions affected by the catecholamines in MS and to evaluate the roles of these potential immunotransmitters.

AB - The mutual involvement of dopamine and its metabolites in the nervous and immune systems has the potential to provide information on the interaction of these two systems. During a 24-hour period, we used capillary electrophoresis with electrochemical detection to repeatedly measure the intracellular catecholamine concentrations in the peripheral blood lymphocytes of relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon (IFN)-beta-1b (n = 13), and those of IFN-naïve RRMS patients receiving their first IFN-beta-1a injection (n = 19) during this study, and compared them with the levels in healthy controls (n = 12). At baseline, the norepinephrine level was significantly decreased (P = 0.003) in the long-term IFN MS patients compared with the controls. The Time × Group interactions for dopamine (P = 0.5854) and norepinephrine (P = 0.6192) were not significant. The group effects for the individual drugs were P = 0.3529 and 0.1282, respectively. The lower norepinephrine level at baseline in the long-term IFN MS group suggests an immunologically stable phase, in line with our previous findings. This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Further studies are necessary to elucidate the immune reactions affected by the catecholamines in MS and to evaluate the roles of these potential immunotransmitters.

KW - Capillary electrophoresis

KW - Catecholamine

KW - Dopamine

KW - Human peripheral blood lymphocyte

KW - Interferon-beta

KW - Multiple sclerosis

KW - Norepinephrine

KW - Relapsing-remitting

UR - http://www.scopus.com/inward/record.url?scp=33744785082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744785082&partnerID=8YFLogxK

U2 - 10.1191/135248506ms1269oa

DO - 10.1191/135248506ms1269oa

M3 - Article

C2 - 16764338

AN - SCOPUS:33744785082

VL - 12

SP - 265

EP - 270

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 3

ER -